2019 Fall Conference Coverage: Live from New Orleans!
Independent Conference Coverage from the CHEST 2019 Annual Meeting*
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Current Perspective on Antifibrotic Therapy for Patients with IPF
Launched: October 25, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (The INBUILD Trial)
Launched: October 25, 2019
Goals of Care Across the Disease Continuum in IPF
Launched: October 25, 2019
Emerging Diagnostic Approaches to Patients with ILD
Launched: October 25, 2019
Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease
Launched: October 25, 2019
Considerations for Geriatric ILD Patients
Launched: October 25, 2019
Nintedanib for Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Launched: October 25, 2019
Inhaled NO in Patients at Risk for Pulmonary Hypertension Associated with Pulmonary Fibrosis
Launched: October 25, 2019
*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2019 CHEST Annual Meeting.
